competitors_report

6.3 Competitors

Slide 1 - Cover (LAVisions layout)layout: title_hero · 16:9
Tola
Competitors Report
A category with a dry pipeline.
CO 01 / 09
Our Competitive Advantage
The quadrant no incumbent holds in 18 to 24 months
Clinical proof on African frontier ingredients, at mid-prestige price, from an operator team.
01
IRB-published clinical proof printed on the carton, not buried in a PDF
02
African frontier actives from a category with a 0.4% study rate
03
Cooperative sourcing at 28% above commodity as a multi-season supply moat
04
Operator team with two prior online-brand exits and a contracted Sephora rollout
Clinical proof depth
Ingredient frontier
Augustinus Bader
The Ordinary
Drunk Elephant
TOLA
CO 02 / 09
Industry Competitive Insight Premium clinical skincare splits across four positions defined by clinical proof and ingredient frontier. The Ordinary owns mass-price ingredient transparency but publishes little proof. Drunk Elephant owns the mid-prestige shelf on marketing-led proof. Augustinus Bader owns ultra-prestige on a single patented molecule at triple the price. The corner with clinical proof on a frontier ingredient at mid-prestige price is empty, and each incumbent would have to move off its own base to take it.
Direct Competitors The Ordinary (Deciem, sold to Estée Lauder April 2024 at $2.2B / 7.3x revenue), Drunk Elephant (sold to Shiseido October 2019 at $845M / 8.4x revenue), and Augustinus Bader (ultra-prestige, TFC8 single-molecule)
Indirect Competitors Reformulation launches from CeraVe and La Roche-Posay, prestige actives from SkinCeuticals and Paula's Choice, and clean-clinical brands like Biossance and Youth to the People
Alternative Approaches Prescription dermatology, in-office procedures, and staying with the five commodity actives the customer already owns
CO 03 / 09
Competitor 1
The Ordinary Mass-price ingredient transparency, limited published proof Deciem's flagship brand, sold to Estée Lauder in April 2024 for $2.2B at 7.3x trailing revenue. Ingredient-list culture at $5 to $15 per product, commodity actives across the range, industry-defining INCI transparency, limited third-party clinical proof.

Features

Single-ingredient formulations at commodity price
Full INCI transparency and active concentration on label
Broad range covering most validated actives
Direct and Sephora distribution at scale
Estée Lauder platform and R&D backing since 2024

Benefits

Educated the market on ingredient transparency and INCI literacy
Lowest price of entry into functional actives
Mass reach across Sephora and direct channels
Trusted by a large, ingredient-literate customer base
Owner-backed distribution and supply scale
Deciem and Estée Lauder announcements | https://deciem.com
CO 04 / 09
Competitor 2
Drunk Elephant Mid-prestige clinical shelf leader, marketing-led proof Sold to Shiseido in October 2019 for $845M at 8.4x trailing revenue. Clean-clinical positioning at $40 to $100 per product, strong Sephora brand awareness, marketing-led rather than IRB-published proof, and a Shiseido-era pipeline slowdown that has ceded the next-active narrative.

Features

Clean-clinical formulations at prestige price
Strong Sephora shelf presence and brand recognition
Bundle and set economics across a full routine
Colour-coded packaging and mixable format story
Shiseido global distribution and supply backing

Benefits

High awareness in the mid-prestige clinical tier
Proven set economics that lift customer value
Established Sephora buyer and merchandising relationships
Loyal repeat base built over a decade
Shiseido scale in manufacturing and international reach
Drunk Elephant and Shiseido announcements | https://drunkelephant.com
CO 05 / 09
Competitor 3
Augustinus Bader Ultra-prestige, patent-led proof on a single molecule Ultra-prestige clinical skincare at $300 and above, built on the patented TFC8 molecule. Patent-led proof and strong brand depth, but a single-molecule narrative that limits product-line breadth and a price tier that excludes the largest growth pool.

Features

Patented TFC8 molecule across the range
Ultra-prestige positioning at $300+ price
Patent-led efficacy claims and lab provenance
Prestige retail and dermatology-adjacent placement
Narrow, disciplined product line

Benefits

Proves demand for science-as-luxury at ultra-prestige
Strong brand depth and pricing authority
Patent protection on the core molecule
High customer value per product
Halo credibility across the clinical category
Augustinus Bader corporate site | https://augustinusbader.com
CO 06 / 09
Competitor Analysis Feature Comparison
Feature TOLA The Ordinary Drunk Elephant Augustinus Bader
IRB-published clinical proof Two hero products, printed on carton Limited published proof Marketing-led, not IRB Patent-led on one molecule
Frontier ingredient story Four African botanical actives Commodity actives Mostly common actives Single proprietary molecule
Price tier Mid-prestige $42 to $94 Mass $5 to $15 Prestige $40 to $100 Ultra-prestige $300+
Single active per product One active, one job Single-ingredient, mix-your-own Multi-active formulations One molecule, full range
Named cooperative sourcing Four cooperatives at 28% over commodity Commodity supply chain Conventional supply Proprietary lab supply
Operator team pedigree L'Oréal, Estée Lauder, Drunk Elephant Estée Lauder owned since 2024 Shiseido owned since 2019 Founder-led, science-branded
CO 07 / 09
Competitive Analysis TOLA occupies the clinical-proof, frontier-ingredient, mid-prestige corner no incumbent holds. TOLA holds a corner no incumbent can take. The Ordinary owns mass-price ingredient transparency but publishes little proof. Drunk Elephant owns the mid-prestige shelf on marketing-led proof, not IRB studies. Augustinus Bader owns ultra-prestige on a single patented molecule at triple the price. Clinical proof on African frontier ingredients, mid-prestige price, and cooperative sourcing at 28% above commodity open an 18 to 24 month window before any of them can respond.

Key Differentiators

IRB-published proof on frontier actives incumbents have not studied
Cooperative sourcing at 28% over commodity as a multi-season moat
Mid-prestige price that captures the largest growth pool

Strategic Implications

Win the shelf and bank the sell-through data before incumbents can copy the claim
Avoid a price fight with The Ordinary, trade the customer up to proof
Take the mid-prestige growth pool Augustinus Bader prices itself out of
CO 08 / 09
References

Competitor Sources

The Ordinary Deciem and Estée Lauder announcements | https://deciem.com
Drunk Elephant Drunk Elephant and Shiseido announcements | https://drunkelephant.com
Augustinus Bader Augustinus Bader corporate site | https://augustinusbader.com

Research Sources

Circana Beauty Brief 2025, US premium skincare $19.2B growing to $26.1B by 2029 | https://www.circana.com
Estée Lauder acquisition of Deciem, April 2024, $2.2B at 7.3x revenue | https://www.esteelauder.com
Shiseido acquisition of Drunk Elephant, October 2019, $845M at 8.4x revenue | https://www.shiseido.com
CO 09 / 09